+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Chlamydia trachomatis infection: Incidence, health costs and prospects for vaccine development



Chlamydia trachomatis infection: Incidence, health costs and prospects for vaccine development



Journal of Reproductive Immunology 48(1): 47-68



Chlamydia trachomatis infection is now the most common sexually transmitted disease worldwide. World Health Organisation figures estimated that 89 million new cases of genital Chlamydia infections occurred in 1995, highlighting the worldwide prevalence of infections and the economic burden on healthcare delivery. A number of methods have been developed for detection of chlamydial infection, which vary in sensitivity and specificity. No single method has yet gained general acceptance and in many countries Chlamydia infections are not reported, suggesting that the above figures may be an underestimate of the problem. As yet there is no consensus as to what constitutes a protective immune response against genital Chlamydia infection. Studies in animal models have shown that cell-mediated immunity, both Th1-driven macrophage activation and cytotoxic T cell responses, as well as antibody can mediate protection at different stages of the chlamydial life cycle. A successful vaccine would probably need to elicit both a systemic cell-mediated immune response to limit/resolve established infections and a mucosal IgA response to reduce bacterial shedding and the resulting spread of infection to partners of infected individuals. The immune response to Chlamydia, either through natural infection or following immunisation, also has the potential to enhance inflammation and to act as a driving force for constant mutations in the variable regions of the major outer membrane protein. As a result a constant prevalence of infection is maintained even in an immune population through the emergence of new allelic variants. Immune responses against antigens such as the 60 kDa heat shock protein can exacerbate inflammation through molecular mimicry and must not be elicited as a result of vaccination. Thus there are many challenges for the development of a successful vaccine which must elicit immunity against multiple serovars while at the same time minimising damaging pro-inflammatory immune responses.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010316421

Download citation: RISBibTeXText

PMID: 10996382

DOI: 10.1016/s0165-0378(00)00069-3


Related references

Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 32(14): 1563-1571, 2014

Chlamydia trachomatis genital infection: immunity and prospects for vaccine development. Inmunologia 24(3): 298-312, 2005

Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects. Expert Review of Vaccines 17(1): 57-69, 2017

Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. Vaccine 2017, 2017

Chlamydia trachomatis infection control programs: lessons learned and implications for vaccine development. Infectious Diseases in Obstetrics and Gynecology 2011: 754060, 2012

Chlamydia trachomatis: Protective Adaptive Responses and Prospects for a Vaccine. Current Topics in Microbiology and Immunology 412: 217-237, 2016

Yearly incidence of Chlamydia trachomatis infection of the cervix in a university student health service population over four years--British Columbia. Canada Diseases Weekly Report 15(36): 181-3; Discussion 183-4, 1989

Chlamydia trachomatis infection and HPV/Chlamydia trachomatis co-infection among HPV-vaccinated young women at the beginning of their sexual activity. Archives of Gynecology and Obstetrics 294(6): 1227-1233, 2016

Infection rate of Chlamydia trachomatis in sexual partners from pregnant women with Chlamydia trachomatis infection. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 67(1): 1-6, 1993

Overview of Chlamydia trachomatis infection and the requirements for a vaccine. Reviews of Infectious Diseases 7(6): 713-716, 1985

Evaluation of incidence of Chlamydia trachomatis infections among the group of infertile women diagnosed by laparoscopy, and based on properties of Chlamydia trachomatis in the cervical canal, peritoneal fluid and ovarian cyst puncture. Ginekologia Polska 72(4): 224-227, 2001

Performance of Chlamydia trachomatis OmcB Enzyme-Linked Immunosorbent Assay in Serodiagnosis of Chlamydia trachomatis Infection in Women. Journal of Clinical Microbiology 56(9), 2018

Trend in Chlamydia trachomatis infection among pregnant women in the past ten years in Japan: significance of Chlamydia trachomatis seroprevalence. Sexually Transmitted Diseases 25(10): 516-521, 1998

Assessment of Chlamydia trachomatis-specific IgA and IgG serum antibodies in genitourinary Chlamydia trachomatis infection--comparative study between HITAZYME and IPAzyme. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 67(4): 315-330, 1993

Studies on diagnosis of infection caused by Chlamydia trachomatis. 1. Micro cell culture method for the isolation and identification of Chlamydia trachomatis. Rinsho Byori. Japanese Journal of Clinical Pathology 36(3): 361-364, 1988